Supraspinatus tendinopathies Musculoskeletal Diseases
Conditions
Interventions
All patients will be subjected to the collection of a blood sample to quantify platelets, and thus, ensure that they are in accordance with the proposed inclusion criteria. The sample will be fraction
Sponsors
Hospital São Paulo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Over 40 years old 2. Pain in the anterolateral shoulder region, without irradiation to the forearm region 3. Pain for more than 3 months of symptoms (measured by Visual Analog Scale) 4. Physical examination (positive Neer test, associated with the Hawkins Kennedy Test and the positive Jobe test) plus magnetic resonance imaging compatible with supraspinatus tendinopathy or partial lesion less than 50%, evaluated by 3 independent evaluators (two orthopedists and a radiologist) 5. Submit and accept the term of clarification and free consent 6. Have not undergone surgery or local injection in the shoulder 7. Agree and sign the free and informed consent form
Exclusion criteria
Exclusion criteria: 1. Bilateral supraspinatus tendon lesions 2. Presence of fractures, surgeries, infiltrations or previous injuries to the affected shoulder 3. Any condition that is a contraindication to interventions 4. Restriction of passive shoulder range of motion on physical examination 5. Signs of other associated diseases on MRI, except acromioclavicular degeneration 6. Platelets of less than 50,000 7. Contraindication to use any component of the proposed treatments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain measured using the visual analog scale at baseline and 1, 2, 4, 8, 12 weeks and 6 months after the procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| At baseline and 1, 2, 4, 8, 12 weeks and 6 months after the procedure: 1. Shoulder function measured using the Shoulder Pain and Diability Index (SPADI), Neer and Hawkins test, and Quick-Dash 2. The range of motion with digital goniometer (flexion, lateral rotation and medial rotation) 3. Shoulder ultrasound examination (evaluation of tendinopathy size and lesion in millimeters) 4. Complications and adverse effects (according to severity and date of occurrence) measured using patient records | — |
Countries
Brazil
Contacts
Public ContactLauro Pajolli
Outcome results
None listed